RecruitingPhase 2NCT07366112

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment of Breast Cancer: ctDNA-Guided Personalized Therapy

Sponsor

Peking University People's Hospital

Enrollment

158 participants

Start Date

Apr 20, 2026

Study Type

INTERVENTIONAL

Conditions

HER2-negative Breast Cancer Hormone Receptor-Positive Breast Cancer Early Stage Breast Cancer High-risk Breast Cancer ctDNA Monitoring

Summary

Exploring the dynamics of ctDNA following neoadjuvant therapy with CDK4/6 inhibitors combined with endocrine treatment, and its potential to guide de-escalation of adjuvant chemotherapy

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CDK4/6 inhibitor with endocrine therapy for people with early stage breast cancer, her2-negative breast cancer, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCDK4/6 inhibitor with endocrine therapy

CDK4/6 inhibitor with endocrine therapy for neoadjuvent therapy

Locations(1)

Peking University People's Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07366112

Related Trials

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT0612028363 locations

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT0546789121 locations